Abstract

ObjectivesTo assess the achievability and effect of attaining low disease activity (LDA) or remission in childhood-onset SLE (cSLE).MethodsAttainment of three adult-SLE derived definitions of LDA (LLDAS, LA, Toronto-LDA), and four definitions of remission (clinical-SLEDAI-defined remission on/off treatment, pBILAG-defined remission on/off treatment) was assessed in UK JSLE Cohort Study patients longitudinally. Prentice–Williams–Petersen gap recurrent event models assessed the impact of LDA/remission attainment on severe flare/new damage.ResultsLLDAS, LA and Toronto-LDA targets were reached in 67%, 73% and 32% of patients, after a median of 18, 15 or 17 months, respectively. Cumulatively, LLDAS, LA and Toronto-LDA was attained for a median of 23%, 31% and 19% of total follow-up-time, respectively. Remission on-treatment was more common (61% cSLEDAI-defined, 42% pBILAG-defined) than remission off-treatment (31% cSLEDAI-defined, 21% pBILAG-defined). Attainment of all target states, and disease duration (>1 year), significantly reduced the hazard of severe flare (P < 0.001). As cumulative time in each target increased, hazard of severe flare progressively reduced. LLDAS attainment reduced the hazard of severe flare more than LA or Toronto-LDA (P < 0.001). Attainment of LLDAS and all remission definitions led to a statistically comparable reduction in the hazards of severe flare (P > 0.05). Attainment of all targets reduced the hazards of new damage (P < 0.05).ConclusionsThis is the first study demonstrating that adult-SLE-derived definitions of LDA/remission are achievable in cSLE, significantly reducing risk of severe flare/new damage. Of the LDA definitions, LLDAS performed best, leading to a statistically comparable reduction in the hazards of severe flare to attainment of clinical remission.

Highlights

  • IntroductionLupus Erythematosus or JSLE) is a multisystem chronic autoimmune/autoinflammatory disorder

  • Childhood-onset Systemic Lupus Erythematosus is a multisystem chronic autoimmune/autoinflammatory disorder

  • The current study aims to assess the achievability of adult-onset SLE (aSLE) low disease activity (LDA) and remission targets in participants of the UK JSLE Cohort

Read more

Summary

Introduction

Lupus Erythematosus or JSLE) is a multisystem chronic autoimmune/autoinflammatory disorder. Children are more severely affected than adults.[1,2,3] Treatment aims to prevent organ damage and optimise health-related quality of life (HRQOL) through minimising disease activity, comorbidities and drug toxicity.[4] Persistent disease activity is associated with rapid accrual of organ damage, protracted corticosteroid therapy and increased mortality.[5] A treat-to-target approach (T2T), where treatment is escalated until a specific target is achieved, and re-escalated if the target is lost, has been proposed as a strategy to improve adult-onset SLE (aSLE) outcomes.[6] initiatives focusing on cSLE are lacking

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call